Home » Newsletters » BioWorld Science

BioWorld Science

Sep. 15, 1999

View Archived Issues

Promising data on Resten-NG presented at international cardiology conference

Finasteride and flutamide compared as therapy for idiopathic hirsutism

Depsipeptide tested in vitro for B-cell CLL inhibition

BiDil combination therapy offers benefits for black CHF patients

Abgenix reports positive preclinical results for ABX-IL-8

Ortho-McNeil designs new prostate-selective alpha1a-adrenoceptor antagonists

New antitumor illudin analogues synthesized at U. of California

Modulators of cGMP production in development at HMR

International patent covers Roche Diagnostics' new anticoagulants

Sulfonylamino MMP inhibitors from Novartis particularly useful for inflammatory disorders, tumors

Novel antiretroviral agents discovered at CNRS

Preclinical studies with lerisetron in models of cisplatin-induced gastric distension and emesis

Company Profile: MacroMed

Effects of dotarizine on intracellular Ca2+ levels explored

Further pharmacological evaluation of abaperidone reported this week at Spanish meeting

Boston Life Sciences and Pfizer sign allergy licensing agreement

Berlex halts Betaseron study for treatment of secondary-progressive multiple sclerosis

News from 23rd IEC: (R)-PID may be preferable to (S)-PID as anticonvulsant

Use of Chiron's IL-2 product for HIV therapy authorized in France

SB and SkyePharma to develop once-daily ReQuip for treatment of PD

Studies on antiepileptic efficacy and mechanism of action of retigabine reported at 23rd IEC

Interleukin Genetics applies for inflammatory gene patent

Nexell begins NIH-funded study to develop tumor cell test

Novavax commences phase III trial of Estrasorb in menopausal women

New phase I/II data on AE-941/Neovastat in lung cancer presented at ECCO 10

Diversa awarded SBIR grants

Corvas and Schering-Plough extend oral anticoagulant research program

Popular Stories

Today's news in brief
BioWorld
Precision psychiatry beyond, or before, biomarkers
BioWorld
There is broad agreement that psychiatric diagnoses in their current form are not reflective of any underlying biology, and that this is one of the things...
Keros reports beneficial effects of RKER-065 in ALS model
BioWorld Science
Keros Therapeutics Inc. has presented data regarding their activin receptor ligand trap, RKER-065, for the inhibition of the activin/myostatin signaling axis.
First-in-class POLG activator restores mtDNA across mutations
BioWorld Science
Researchers from Pretzel Therapeutics Inc. presented preclinical data of PX-578, a first-in-class POLG activator aimed at restoring mtDNA replication and...
News in brief
BioWorld Asia
BioWorld Asia briefs for March 17, 2026